These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31393188)

  • 1. HCV treatment with direct acting antivirals improves the insulin sensitivity.
    Alsebaey A; Elhelbawy M; Abdel-Razek W; Hashim M; Elshenawy H; Waked I
    Expert Rev Anti Infect Ther; 2019 Sep; 17(9):749-754. PubMed ID: 31393188
    [No Abstract]   [Full Text] [Related]  

  • 2. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Elhelbawy M; Abdel-Razek W; Alsebaey A; Hashim M; Elshenawy H; Waked I
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):16-23. PubMed ID: 30024489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
    Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
    Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
    Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
    Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
    Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
    Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
    J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR.
    Strauhs-Nitsch L; Campiolo MF; Morsoletto DBG; Pissaia Junior A; Ivantes CAP
    Arq Gastroenterol; 2020; 57(3):267-271. PubMed ID: 33027477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of hepatitis c virus infection status with serum glucose levels.
    Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
    BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
    Dai CY; Huang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Hepatol; 2009 Apr; 50(4):712-8. PubMed ID: 19231011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
    J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving relationship between adiponectin and insulin sensitivity in hepatitis C patients during viral clearance.
    Chang ML; Kuo CJ; Pao LH; Hsu CM; Chiu CT
    Virulence; 2017 Oct; 8(7):1255-1264. PubMed ID: 28267407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
    Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
    Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
    Abd El-Wahab EW; Mikheal A; Sidkey F; Shatat HZ
    J Med Virol; 2015 Mar; 87(3):428-40. PubMed ID: 25583244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study).
    Boraie MB; Elnaggar YA; Ahmed MO; Mahmoud AM
    Diabetes Metab Syndr; 2019; 13(4):2641-2646. PubMed ID: 31405688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection.
    Ichikawa T; Miyaaki H; Miuma S; Motoyoshi Y; Narita S; Toda S; Takahashi Y; Honda T; Yajima H; Uehara R; Hino N; Hori T; Hirata R; Taura N; Nakao K
    Intern Med; 2019 May; 58(9):1209-1215. PubMed ID: 30626818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients.
    Khattab M; Eslam M; Sharwae MA; Shatat M; Ali A; Hamdy L
    Am J Gastroenterol; 2010 Sep; 105(9):1970-7. PubMed ID: 20234345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Mousa N; Abdel-Razik A; Farag R; Shabana W; Elgamal A; El-Wakeel N; Elzehery R; Elkashef W; Eldars W
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1004-1009. PubMed ID: 28749790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.